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paroxysmal nocturnal Hemoglobinuria presenting with a Left 
Intraventricular Thrombus in a patient with prior Thymoma 
and Aplastic Anemia
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Abstract: We report the case of a 37-year old man presenting with a left ventricular cardiac thrombus in the setting of subclinical 
paroxysmal nocturnal hemoglobinura (PNH) developing two years after immunosuppressive therapy for thymoma-associated aplas-
tic anemia. The literature regarding the interplay between autoimmunity and immunosuppression, aplastic anemia, thymoma and the 
  emergence of PNH is reviewed.
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case Report
A  previously  healthy,  37-year  old  man  presented 
  initially in December 2004 with epistaxis, petechial 
rash  and  severe  pancytopenia  (absolute  neutrophil 
count  ANC  400/µL,  hemoglobin  7.7  g/dL,  plate-
lets 3 × 103/µL). Bone marrow biopsy demonstrated 
severely hypocellular marrow with polyclonal lym-
phoid  aggregates  and  normal  karyotype,  consistent 
with severe aplastic anemia (Fig. 1). Viral serologies, as 
well as CD55/59 flow cytometry screening were neg-
ative. A CT scan performed during the initial workup 
revealed an 8 cm lobulated anterior mediastinal mass. 
The patient underwent a biopsy and subsequent thora-
cotomy, which revealed type B (cortical epithelioid) 
thymoma with evidence of the innominate vein inva-
sion, infiltration of mediastinal fat and positive surgi-
cal margin, prompting subsequent adjuvant radiation 
to the surgical bed. Despite treatment of thymoma, 
there was no observed hematologic improvement in 
the aplastic anemia with continued, heavy transfusion 
dependence. The patient was evaluated for allogeneic 
bone marrow transplantation, but he did not have an 
eligible sibling and declined the option of a matched 
unrelated  donor  transplantation.  He  was  treated 
with the standard course of antithymocyte globulin 
(ATG) and cyclosporine A without any evidence of 
  hematologic response during the subsequent 6 months 
of support with nearly weekly platelet and/or red cell 
transfusions. However, over the course of the ensu-
ing year his transfusion requirements spontaneously 
decreased and he ultimately achieved a partial remis-
sion from aplastic anemia. Since December 2006 he 
did not require any further transfusions.
In November 2007, a routine surveillance CT scan 
of the chest incidentally showed a filling defect within 
the apex of the left cardiac ventricle, suspicious for 
a  malignancy  or  thrombosis.  Further  investigation 
with  a  2D  echocardiogram,  cardiac  catheterization 
and MRI (Fig. 2) confirmed a 3.4 cm tethered, mobile 
intraventricular mass and no cardiac function abnor-
mality. The patient was anticoagulated with warfarin, 
however after 2 months there was no resolution of the 
lesion and excision was recommended.
Considering prior median sternotomy, the mass was 
removed by minimally invasive thoracotomy under 
cardiopulmonary bypass. Pericardium was accessed 
through a small right lateral thoracotomy in the third 
intercostal  space,  with  exposure  of  the  interatrial 
septum  above  the  pulmonary  veins  and  dissection 
of paraaortic adhesions. Antegrade cardioplegia was 
delivered after heparinization. The mass was accessed 
via left atrium with retraction of the anterior leaflet of 
the mitral valve. It appeared as a   yellowish fibrous 
structure attached to the trabeculations in the apex. 
The lesion was pathologically identified as organizing 
thrombus with peripheral fibroblast   proliferation and 
fibrin inflammatory debris. There was no evidence of 
antiphospholipid  antibodies,  other  thrombophilias, 
abnormal cardiac function or coronary vessel pathol-
ogy.  However,  a  repeat  CD55/59  flow  cytometry 
confirmed a new diagnosis of paroxysmal nocturnal 
hemoglobinuria (PNH), with over 80% CD55/59-de-
ficient red cells and granulocytes (Fig. 3). Continued 
anticoagulation was prescribed.
At that point there was only mild chronic hemo-
lysis (hemoglobin 11 g/dL, LDH 380 IU/L) and the 
patient did not require any intervention except for 
continued anticoagulation and monitoring. However, 
in June 2011 he sustained an episode of severe hemo-
lysis (with a hemoglobin drop from 13.2 to 6.3 g/dL) 
following an upper respiratory tract infection, com-
plicated  by  acute  renal  failure.  Upon  recovery,  he 
was reevaluated for potential allogeneic bone mar-
row transplantation and eculizumab therapy. Figure 4 
tracks the history of the patient’s cytopenias on the 
background of clinical events.
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Figure 1. Microscopic images of the bone marrow biopsy. (A) low-power 
magnification  of  May-Grunwald/Giemsa  stain  showing  hypocellular 
  marrow with a lymphoid germinal center. (B) high-power view demon-
strating decreased hematopoiesis with interspersed lymphocytes. CD3, 
CD20: immunohistochemical stains highlighting mixed, polyclonal nature 
of T and B-lymphocytes in the tissue.Intraventricular thrombus in pNH
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Figure 2. Images of the cardiac magnetic resonance imaging (MrI) and 2D echocardiogram sequence visualizing the intraventricular thrombus. (A) MrI, 
coronal projection, inversion-recovery fast low-angle shot sequence (FLASH). (B) MrI, four-chamber axial image from the steady-state free-precession 
sequence. (c) echo, two-chamber apical window showing a homogenous echodensity in the apex. (D) four-chamber apical window. (e) short axis 
  parasternal view.
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Figure 3. CD59 red cell flow cytometry histogram at the initial presentation and at the time of thrombus diagnosis, when a bimodal distribution with a 
dominant pNH clone became manifest.Migdady and Olszewski
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Discussion
Paroxysmal  nocturnal  hemoglobinuria  is  a  rare 
clonal stem cell disorder, characterized by chronic 
  intravascular hemolysis, highly thrombophilic state 
and progression to bone marrow failure, commonly 
after a period of sustained hematopoiesis.1 The patho-
genesis of this disorder involves a somatic mutation 
in  the  PIG-A  gene  with  consequent  deficiency  in 
glycosylphosphatidylinositol(GPI)-anchored  mem-
brane proteins, such as surface complement deacti-
vators CD55 (decay-accelerating factor) and CD59 
(protectin). This deficit leads to complement-mediated 
red cells lysis, increased platelet reactivity, abnormal 
fibrinolysis and a number of other pathophysiologic 
phenomena  producing  a  hypercoagulable  state.2 
Intravascular hemolysis with release of free plasma 
hemoglobin contributes to nitric oxide deficiency and 
endothelial  dysfunction  in  a  mechanism  that  links 
thrombotic risk in PNH and other hemolytic disorders 
such as sickle cell disease.3
Thrombosis, the major source of morbidity and 
mortality in PNH, typically occurs within the venous 
circulation,  frequently  in  unusual  sites,  such  as 
hepatic or splanchnic veins, cavernous sinus etc. The 
10  year  cumulative  incidence  of  venous  thrombo-
sis among all affected patients is 23% and depends 
on the size of the abnormal clone. Intraventricular 
cardiac thrombi have not been previously reported in 
association with this disease. Thrombosis within the 
left ventricle occurs almost exclusively in the setting 
of pre-  existing heart failure. In a recent review only 
seven prior cases of left ventricular thrombus with 
preserved  cardiac  function  were  reported,  mostly 
with a history of prothrombotic medical conditions.4
Arterial  thrombosis  occasionally  does  occur  in 
PNH. Among nine patients with acute stroke and PNH, 
in five cases the thrombosis was one of the first mani-
festations of the hematologic disorder.5 In the largest 
descriptive series, cases of arterial thrombosis in the 
central nervous system, coronary circulation, hepatic, 
mesenteric arteries and aorta were   summarized.6 The 
arterial  events  were  classified  as  high-risk  despite 
their relatively low incidence. They occurred mostly 
in young patients without underlying atherosclerosis. 
However, the relative risk of coronary event was over 
20 and cardiac thrombosis was associated with the 
highest mortality score.
The  disturbed  coagulation  system  in  low-shear, 
slow-flow  venous  circulation  is  believed  to  play 
the  dominant  role  in  the  pathogenesis  of  venous 
  thromboembolism, while platelet pathology is typically 
implicated in   arterial thrombosis. Interestingly, platelet 
activation was reported in PNH and antiplatelet therapy 
was  suggested  as  possible  therapeutic  intervention.7 
Platelets just as other blood cells originate from the 
pathologic clone and are prone to complement-medi-
ated injury and activation. Circulating platelet-derived 
procoagulant microparticles rich in phospholipids were 
detected in PNH and may contribute to the thrombotic 
risk.8  In  case  of  either  venous  or  arterial  thrombo-
sis, anticoagulation remains the mainstay of therapy. 
Recent reports highlight decrease in thrombotic risk 
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Figure 4. Tracing of the patient’s cytopenias (platelets—green, haemoglobin—red, neutrophil count—blue) on the backdrop of the clinical events.Intraventricular thrombus in pNH
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after treatment with eculizumab (monoclonal antibody 
against the complement protein 5).9
The  occurrence  of  contemporaneous  malignant 
thymoma and severe aplastic anemia with subsequent 
PNH in our case sheds additional light on the com-
plex interaction between thymoma-derived autoim-
munity, T-cell directed immunosuppression and the 
dynamics  of  PNH  clone  emergence  and  survival. 
Sensitive  assays  detect  cells  with  PNH  phenotype 
in over 50% of patients with acquired AA, and the 
emergence of a PNH clone in AA had been previously 
reported in 10%–25% of cases after immunosuppres-
sive   therapy.10 In the era of sensitive flow cytometry 
screening,  although  there  is  a  large  proportion  of 
PNH-positive patients at the onset of AA, the occur-
rence of a new clone years later is not common.11 
In the majority of patients with a detectable mutant 
population, the proportion of PNH cells ultimately 
decreased after immunosuppressive therapy.12
Thymoma  often  produces  paraneoplastic  autoim-
mune disorders, such as myasthenia gravis, pure red cell 
aplasia and AA. In the single previously reported case 
of PNH occurring after resection of thymoma, circu-
lating myelotoxic CD8+ lymphocytes were detected.13 
It is hypothesized that while PIG-A mutations occur 
sporadically in healthy population, impaired immune 
surveillance or autoattack against normal progenitors 
is critical for expansion and hematopoietic dominance 
of the PNH clone. The mutant population has the abil-
ity to restore hematopoiesis—in our patient ironically 
leading to remission from severe aplastic anemia unre-
sponsive  to  standard  treatment.  Such  a  paradoxical 
mechanism had been conjectured in the past.14
Yearly  screening  for  PNH  in AA  patients  after 
therapy  has  been  recommended  by  the  Interna-
tional PNH Interest Group, although the benefits and 
  duration of such screening remain uncertain.15 While 
prospective series do not uphold earlier postulations 
that overt PNH should frequently develop in patients 
with AA harboring a small CD55/59 deficient popu-
lation, our case underscores the importance of longi-
tudinal follow up and screening.16 The appearance of 
a new large PNH clone, while uncommon, warrants 
prophylactic anticoagulation, since the risk of throm-
bosis approaches 50% over 10 years.17 Cardiac sur-
gery in the setting of PNH may be complicated with 
increased risk of hemolysis, renal failure and throm-
bosis, so additional perioperative interventions have 
been recommended.18 In case of clinically overt PNH, 
treatment  with  eculizumab  is  effective  in  decreas-
ing hemolysis, transfusion dependence and the risk 
of thrombosis.19 It also favorably affects survival in 
patients with PNH.20 As our case illustrates, a seem-
ingly spontaneous, delayed remission from AA may 
occur  thanks  to  the  emergence  of  hematologically 
effective PNH, which nevertheless can manifest its 
own thrombotic and hemolytic consequences.
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